We Work to Give Medical Professionals the Tools They Need

Alnylam is committed to supporting and partnering with the healthcare community, across many disease areas. This includes providing information on our research and treatments in development.

Acting “Upstream” of Today’s Medicines

With investigational RNAi therapeutics, we believe it may be possible to block the production of disease-causing proteins before they are made.

More About RNAi ›



Late Stage

Learn more about our investigational therapies in hereditary ATTR amyloidosis, hemophilia, acute hepatic porphyria, and primary hyperoxaluria type 1.

Early Stage

Learn more about our investigational therapies across multiple disease areas.

Alnylam Grant Information

Alnylam is committed to supporting the medical and scientific understanding of our therapeutic areas of interest for healthcare professionals. Additionally, we are committed to supporting educational programs and initiatives spearheaded by organizations focused on patient advocacy, community education and support, and other scientific efforts related to our therapeutic areas of interest.


The following are the available Request for Grant Proposals:

Consensus Guidelines on the Identification and Diagnosis of Porphyrias.

Differential Identification of Rare Causes of Motility Disorders (REGP 3a)

Understanding the early constellation of symptoms associated with hereditary TTR amyloidosis (REGP 3b)

Educational Grant

To submit a request for funding related to a grant, please email your requests or inquiries to Grant requests should include, at a minimum*, the following:


*Please note that some grants have specific requirements


To submit a request for an Independent Medical Education (IME) activity, please visit


To submit a request for funding related to a sponsorship, please email your requests or inquiries to Sponsorship requests should include, at a minimum, the following:


Access to Investigational Medicines

Alnylam is dedicated to developing new therapies that have a positive impact on patient health, and to serving patients, patient families, and patient communities through education, empathy, and awareness. We understand that there are seriously ill patients who will not be eligible for our clinical trials and may not have options for alternative therapies, including investigational therapies in trials being conducted by other sponsors. In these circumstances, Alnylam will consider providing a requesting physician with pre-approval access to a specific Alnylam investigational medicine, for the treatment of an individual patient outside of a clinical trial, when certain conditions are met.


To read our statement on access to investigational medicines, click here.


Learn more about an FDA-approved treatment option available for patients in the U.S.

Learn More ›


Alnylam AssistTM helps patients access ONPATTRO® (patisiran) with personalized support.

Visit Site ›


Alnylam Act provides no-charge, independent genetic testing and counseling to individuals in the US and Canada who may have hATTR amyloidosis, acute hepatic porphyria, or primary hyperoxaluria type 1 (PH1).

Get More Info ›


Learn more about the signs and symptoms of AHP, and how to guide your patients to a clear diagnosis.

Start Here ›


Receive news and updates on the work at Alnylam that affects you most.